Raloxifene
Also known as: Raloxifene hydrochloride, LY156758, Evista
Classification
Serm
Regulatory Status
FDA-approved prescription product (Evista)
Sources
7
Review
n/a
Overview
Raloxifene acts as a selective estrogen receptor modulator, binding estrogen receptors to produce tissue-selective estrogen-agonist effects (e.g., decreased bone resorption and increased bone mineral density) alongside estrogen-antagonist effects in other tissues such as breast and endometrium.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Raloxifene acts as a selective estrogen receptor modulator, binding estrogen receptors to produce tissue-selective estrogen-agonist effects (e.g., decreased bone resorption and increased bone mineral density) alongside estrogen-antagonist effects in other tissues such as breast and endometrium.
Benefits
FDA-approved EVISTA (raloxifene hydrochloride) labeling includes treatment and prevention of osteoporosis in postmenopausal women. Educational reference only.
Labeled to reduce risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk for invasive breast cancer. Educational reference only.
Interactions & cautions
Drug interactions
cholestyramine and other anion exchange resins — May significantly reduce raloxifene absorption. (review)
systemic estrogens — Concomitant systemic estrogen is not recommended in labeled practice contexts. (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.